

## DAFTAR PUSTAKA

1. Non-small cell lung cancer survival rates, by stage. American Cancer Society. <http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates>. Diakses pada 17 Mei, 2021.
2. Shi Y, Au JS-K, Thongprasert S, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). *J Thorac Oncol.* 2014; 9(2):154–162. DOI: 10.1097/JTO.000000000000033 [PubMed: 24419411].
3. Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European KPKBSK patients: data from daily practice. *Br J Cancer.* 2013; 109(7):1821–1828. DOI: 10.1038/bjc.2013.511 [PubMed: 24002608]
4. Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. *Int J Cancer.* 2012; 131(5):E822–E829. DOI: 10.1002/ijc.27396 [PubMed: 22161771]
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. *N Engl J Med.* 2010; 362(25):2380–2388. DOI: 10.1056/NEJMoa0909530 [PubMed: 20573926]
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012; 13(3):239–246. DOI: 10.1016/S1470-2045(11)70393-X [PubMed: 22285168]
7. Rosell R, Moran T, Queralt C, et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. *N Engl J Med.* 2009; 361(10):958–967. DOI: 10.1056/NEJMoa0904554 [PubMed: 19692684]
8. Zhang Y, Sheng J, Kang S, et al. Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. *PLoS One.* 2014; 9(9):e107161.doi: 10.1371/journal.pone.0107161 [PubMed: 25222496]
9. Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-

- resistant patients with non-small-cell lung cancer. *Lancet Oncol.* (2015) 16:e447–59. doi: 10.1016/S1470-2045(15)00246-6
10. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med.* (2011) 3:75ra26. doi: 10.1126/scitranslmed.3002003
  11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med.* (2005) 352:786–92. doi: 10.1056/NEJMoa044238
  12. Stinchcombe TE. AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. *Transl Lung Cancer Res.* (2016) 5:92–4. doi: 10.3978/j.issn.2218-6751.2015.07.19
  13. Odogwu L, Mathieu L, Goldberg KB, Blumenthal GM, Larkins E, Fiero MH, et al. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation. *Oncologist.* (2018) 23:353–9. doi: 10.1634/theoncologist.2017-0425
  14. Elena V, Mishina PD, Sripal Mada PD. Clinical pharmacology biopharmaceutics review(s) (2009). Available online at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022307s000\\_ClinPharmR\\_p1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022307s000_ClinPharmR_p1.pdf)
  15. Kuiper JL, Heideman DAM, Thunnissen E, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated KPKBSK-patients. *Lung Cancer.* 2014; 85(1):19–24. DOI: 10.1016/j.lungcan.2014.03.016 [PubMed: 24768581]
  16. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. *Clin Cancer Res.* 2011; 17(6):1616–1622. DOI: 10.1158/1078-0432.CCR-10-2692 [PubMed: 21135146]
  17. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;caac.21660. Available from: <https://onlinelibrary.wiley.com/doi/10.3322/caac.21660>
  18. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. *Ann Glob Heal.* 2019;85(1). Available from: [/pmc/articles/PMC6724220/](https://pubmed.ncbi.nlm.nih.gov/3482220/)

19. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. *J Thorac Oncol*. 2015;10(9):1243–60. Available from: <http://www.jto.org/article/S1556086415335711/fulltext>
20. Tsao M. PL01.05 The New WHO Classification of Lung Tumors. *J Thorac Oncol*. 2021;16(3):S63. Available from: <http://www.jto.org/article/S1556086421000460/fulltext>
21. Kumar V, Abbas AK, Aster JC, Turner JR, editors. Neoplasia. In: Robbins & Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021. p. 269.
22. Global Cancer Observatory. World Fact Sheets [Internet]. 2020. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>
23. Global Cancer Observatory. Indonesia Fact Sheets [Internet]. 2020. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
24. Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer. *Cancer Epidemiol Biomarkers Prev*. 2019;28(10):1563–79. Available from: </pmc/articles/PMC6777859/>
25. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network. *Nature*. 2014;511(7511):543–50. Available from: </pmc/articles/PMC4231481/>
26. Roh MS. Molecular pathology of lung cancer: Current status and future directions. *Tuberc Respir Dis (Seoul)*. 2014;77(2):49–54. Available from: </pmc/articles/PMC4165659/>
27. Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. *Cancer Sci*. 2016;107(6):713–20. Available from: </pmc/articles/PMC4968599/>
28. Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: Current status and perspectives. *Curr Opin Oncol*. 2018;30(2):69–76. Available from: <https://pubmed.ncbi.nlm.nih.gov/29251665/>
29. Uras IZ, Moll HP, Casanova E. Targeting KRAS mutant non-small-cell lung cancer: Past, present and future. *Int J Mol Sci*. 2020;21(12):1–30. Available from: </pmc/articles/PMC7352653/>
30. O’Leary CG, Andelkovic V, Ladwa R, Pavlakis N, Zhou C, Hirsch F, et al. Targeting BRAF mutations in non-small cell lung cancer. *Transl Lung*

- Cancer Res.* 2019;8(6):1119–24. Available from: [/pmc/articles/PMC6976351/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
31. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. *Lung Cancer*. 2015;87(3):220–5. Available from: <https://pubmed.ncbi.nlm.nih.gov/25601485/>
  32. Liang H, Wang M. MET oncogene in non-small cell lung cancer: Mechanism of MET dysregulation and agents targeting the HGF/c-met axis. *Onco Targets Ther*. 2020;13:2491–510. Available from: [/pmc/articles/PMC7104217/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
  33. Kim D, Lee YS, Kim DH, Bae SC. Lung cancer staging and associated genetic and epigenetic events. *Mol Cells*. 2020;43(1):1–9. Available from: [/pmc/articles/PMC6999714/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
  34. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. *J Thorac Oncol*. 2016;11(1):39–51. Available from: <https://pubmed.ncbi.nlm.nih.gov/26762738/>
  35. Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et al. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. *J Thorac Oncol*. 2019;14(3):377–407. Available from: [/pmc/articles/PMC6422775/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
  36. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. In: *Archives of Pathology and Laboratory Medicine*. College of American Pathologists; 2018. p. 321–46. Available from: <https://pubmed.ncbi.nlm.nih.gov/29355391/>
  37. Jones GS, Baldwin DR. Recent advances in the management of lung cancer [Internet]. Vol. 18, *Clinical Medicine*, Journal of the Royal College of Physicians of London. Royal College of Physicians; 2018. p. s41–6. Available from: [/pmc/articles/PMC6334032/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
  38. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. *Acta Pharm Sin B*. 2015;5(5):390–401. doi:10.1016/j.apsb.2015.07.001.
  39. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-

- cell lung cancer. *J Clin Oncol.* 2010;28(2):357-360. doi:10.1200/JCO.2009.24.7049
40. Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. *Pharmacol Res.* 2016;103:26-48. doi:10.1016/j.phrs.2015.10.021.
  41. A.C. Dar, K.M. Shokat, The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling, *Annu. Rev. Biochem.* 80 (2011) 769–795.
  42. Chen Y-L, Lin C-C, Yang S-C, et al. Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison. *Front Oncol.* 2019;9(July):1-8. doi:10.3389/fonc.2019.00631.
  43. Passiglia F, Rizzo S, Maio M Di, et al. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in KPKBSK: a systematic review and meta-analysis. *Sci Rep.* 2018;8(1):1-10. doi:10.1038/s41598-018-30780-4.
  44. Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB. Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (KPKBSK). *Clinical lung cancer.* 2018 Jan 1;19(1):e19-28.
  45. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. *Clin Cancer Res.* 2011;17(6):1616–22. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060283/>
  46. Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun SM, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. *BMC Cancer.* 2013;13:606. Available from: [/pmc/articles/PMC3877961/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961/)
  47. Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. *Sci Rep.* 2016;6. Available from: [/pmc/articles/PMC5095551/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095551/)
  48. Ma G, Zhang J, Jiang H, Zhang N, Yin L, Li W, et al. Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors. *Oncotarget.* 2017;8(59):99429–37. Available from: [/pmc/articles/PMC5725104/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725104/)

49. Joo JW, Hong MH, Shim HS. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. *Lung Cancer*. 2018;121:12–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/29858020/>